ACTG 370:VIROLOGIC & IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VS

ACTG 370：病毒学

• 批准号: 6264447
• 负责人: ROBERT KALAYJIAN
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264447
• 关键词: AIDS therapy; HIV infections; clinical research; combination chemotherapy; delavirdine; human subject; human therapy evaluation; indinavir; lamivudine

CORE LAB ONLY - SAMPLE PROCESSING. Recent advances in our understanding of the dynamic nature of HIV infection and of the importance of HIV-1 replication in disease pathogenesis, coupled with the advent of new potent antiretroviral agents such as the protease inhibitors, have led to the development of new treatment paradigms. For most patients, three-drug regimens including two reverse transcriptase (RT) inhibitors and a protease inhibitor are needed to reduce and maintain plasma levels of HIV-1 RNA below the limits of detection. Despite the success of these regimens, treatment failures may occur for a variety of reasons. This study addresses the question of whether to discontinue lamivudine or substitute the non-nucleoside RT inhibitor delavirdine when adding indinavir to patients previously treated with didanosine, or d4T plus 3TC who have >500 copies/ml of plasma HIV-1 RNA.

仅限核心实验室-样品处理。最近，我们对HIV感染的动态性质和HIV-1复制在疾病发病机制中的重要性的了解取得了进展，加上新的有效抗逆转录病毒药物的出现，如蛋白酶抑制剂，导致了新的治疗范例的发展。对于大多数患者，需要三种药物方案，包括两种逆转录酶(RT)抑制剂和一种蛋白酶抑制剂，以降低并保持血浆中HIV-1RNA水平低于检测极限。尽管这些疗法取得了成功，但由于各种原因，治疗失败的情况可能会发生。这项研究解决的问题是，对于血浆HIV-1RNA拷贝数为500拷贝/毫升的患者，在给以前接受地达那新或d4T加3TC治疗的患者添加indinavir时，是否停止使用拉米夫定或替代非核苷类RT抑制剂delavidine。